
HOME		SEARCH		RSS FEED		SUBSCRIBE

Search Results - nxxxxx

22 Results

Sort By:

Diffusion Through Skull as Route of Delivery for Treatment of Brain Injury and Disease

Traumatic Brain injury (TBI) often results from head impact and is a major cause of death and disability. Brain injuries vary in severity and can be associated with hemorrhaging, swelling, inflammation, and death of brain tissue. Inventors at NINDS developed a novel approach to treating brain injuries that involves transcranial application of small...

Published: 7/25/2024 | Inventor(s): Theodore Roth, Dorian McGavern

Keywords(s): AB3DXX, AB3XXX, ABXXXX, AXXXXX, brain, Delivery, diffusion, Disease, INJURY, NB1JXX, NB1XXX, NBXXXX, NXXXXX, Route, Skull, TREATMENTS

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Neurology, Application > Therapeutics

Derivatives of Docosahexaenoylethanolamide (DEA) for Neurogenesis

The invention pertains to derivatives of docosahexaenoylethanolamide (synaptamide or DEA) and their use in inducing neurogenesis, neurite growth, and/or synaptogenesis. As such, these DEA derivatives can be used as therapeutics for neurodegenerative diseases such as traumatic brain injury, spinal cord injury, peripheral nerve injury, stroke, multiple...

Published: 7/25/2024 | Inventor(s): Erika Englund, Juan Marugan, Samarjit Patnaik, Hee-Yong Kim

Keywords(s): Derivatives, Development, Discovery, Docosahexaenoylamide, Growth, IB6XXX, IBXXXX, IXXXXX, Listed LPM Vepa as of 4/15/2015, NB1FXX, NB1HXX, NB1XXX, NBXXXX, Neurons, NXXXXX, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Promote, That, VEXXXX, YAXXXX, YBXXXX, YFXXXX

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Neurology, Application > Diagnostics, TherapeuticArea > Reproductive Health, Application > Research Materials, Application > Vaccines, Application > Therapeutics

SIRT2 Inhibitors as Novel Therapeutics for Myocardial Infarction and Ischemic Stroke and to Prevent Necrosis

Sirtuin 2 (SIRT2) inhibitors to reduce necrosis and, thereby, as novel therapeutics to treat ischemic stroke and myocardial infarction. Accumulating evidence indicates that programmed necrosis plays a critical role in cell death during ischemia-reperfusion. NIH investigators have shown that the NAD-dependent deacetylase SIRT2 binds constitutively...

Published: 4/8/2024 | Inventor(s): Toren Finkel, Nisha Narayan

Keywords(s): Against, AGK2, deacetylase, IB1FXX, IB1XXX, IBXXXX, inhibitor, IXXXXX, NAD-dependent, NB1HXX, NB1XXX, NBXXXX, NECROSIS, NXXXXX, PROTECTS, Sirt2

Category(s): Collaboration Sought > Collaboration, Application > Diagnostics, Application > Research Materials, Application > Therapeutics, TherapeuticArea > Cardiology, TherapeuticArea > Neurology

Axon Regeneration After Brain or Spinal Cord Injury

The invention is directed to modification of a particular sugar by the enzyme arylsulfatase B (ARSB), which results in axon regeneration. Following traumatic brain or spinal cord injury, glial scars prevent regeneration of axons. Chondroitin sulfate proteoglycans (CSPGs) are major components of glial scars. CSPGs are made of a protein core containing...

Published: 7/25/2024 | Inventor(s): Yasuhiro Katagiri, Herbert Geller

Keywords(s): AFTER, Arylsulfatase, AXONAL, B, Brain/spinal, CORD, INJURY, NB1JXX, NB1XXX, NBXXXX, NXXXXX, PROMOTES, Regeneration

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Neurology

Small Molecule MRS5474 with Anticonvulsant Activity for Treatment of Epilepsy

Adenosine modulates many physiological processes by activating specific adenosine receptors. These adenosine receptors play a critical role in the regulation of cellular signaling and are broadly distributed throughout the body. Thus, the ability to modulate adenosine receptor-mediated signaling is an attractive therapeutic strategy for a broad range...

Published: 7/25/2024 | Inventor(s): Dilip Tosh, Kenneth Jacobson

Keywords(s): A3, Activity, ADENOSINE, AGONISTS, Agonists:, Al, ANTAGONISTS, Anticonvulsant, Derivatives, Docking, IB1FXX, IB1XXX, IBXXXX, IXXXXX, NB1EXX, NB1HXX, NB1XXX, NBXXXX, N-Methanocarba, Nucleosides, NXXXXX, PARTIAL, Patent Category - Chemistry, POTENT, RECEPTOR, TRUNCATED

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Neurology, Application > Diagnostics, Application > Research Materials, TherapeuticArea > Cardiology, Application > Therapeutics

Cyclodextrins as Therapeutics for Lysosomal Storage Disorders

Cyclodextrins (CD), alone or in combination with other agents (e.g., vitamin E), as therapeutics for the treatment of lysosomal storage disorders (LSDs) caused by the accumulation of non-cholesterol lipids. CDs are sugar molecules in a ring form. The alpha-CD (6 sugars), beta-CD (7 sugars) and gamma-CD (8 sugars) are commonly used cyclodextrins. The...

Published: 7/25/2024 | Inventor(s): Wei Zheng, Miao Xu, Manju Swaroop, Juan Marugan, John McKew

Keywords(s): Combination, CYCLODEXTRIN, DISEASES, e, IB6XXX, IBXXXX, IXXXXX, Lysosomal, NB1JXX, NB1XXX, NBXXXX, NXXXXX, Storage, treatment, UA1XXX, USES, Vitamin

Category(s): Collaboration Sought > Collaboration, Application > Research Materials, Application > Diagnostics, Application > Vaccines, TherapeuticArea > Rare / Neglected Diseases, Application > Therapeutics, TherapeuticArea > Neurology, TherapeuticArea > Reproductive Health

M5 Muscarinic Receptor Knockout (Chrm5tm1Jwe) Mouse Model for Neurological Studies

M5 muscarinic receptor knockout: Deficiency of M5Rs reduces drug-seeking behavior. The five Muscarinic Acetylcholine (ACh) receptors are G-protein coupled receptors (M1R-M5R). M1R, M3R and M5R selectively couple to Gq/G11; M2R and M4R selectively couple to Gi/Go. M5R knockout mice are viable and fertile, and have no major morphological abnormalities. M5...

Published: 7/25/2024 | Inventor(s): Jurgen Wess

Keywords(s): Chrm5, Knock, M5, Mouse, MUSCARINIC, NCXXXX, NXXXXX, RECEPTOR, TmJwe

Category(s): Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Neurology

Therapeutic Approach to Neurodegenerative Disorders Using a TFP5-Peptide

This invention discloses methods for treating neurodegenerative diseases by administering cyclin dependent kinase 5 (Cdk5) inhibitory peptides derived from P35, the activator of Cdk5. Abnormally hyperactive Cdk5 has been shown to be associated with a variety of neurodegenerative disorders. Disclosed in this invention are isolated peptide fragments,...

Published: 7/25/2024 | Inventor(s): Harish (Estate of) Pant

Keywords(s): Approach, DISORDERS, NB1BXX, NB1FXX, NB1XXX, NBXXXX, NEURODEGENERATIVE, NXXXXX, TFP5-peptide, therapeutic

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Neurology

Phantasmidine, a Nicotinic Receptor Agonist for the Treatment of Addiction and Neurological Disorders

The inventors have isolated and characterized an alkaloid, phantasmidine, from the skin of the Ecuadoran poison frog E. anthonyi. Phantasmidine is selective for beta4-containing receptor subtypes, unlike many nicotinic receptor agonists currently in development, which target beta2-containing receptor subtypes. This selectivity makes phantasmidine...

Published: 7/25/2024 | Inventor(s): Richard Fitch

Keywords(s): ADDICTION, AGONIST, Alkaloid, Alzheimer disease 1, Alzheimer disease 3, Alzheimer disease 4, Alzheimer disease type 1, Alzheimer disease type 4, Alzheimer disease, familial, type 3, EPIBATIDINE, IBXXXX, IXXXXX, nAChR, NBXXXX, NC2XXX, NCXXXX, Neurological, neurological disease, nicotine, NICOTINIC, NXXXXX, Patent Category - Chemistry, Phantasmidine

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Neurology, Application > Research Materials, Application > Diagnostics

Prevention and Treatment of Multiple Sclerosis (MS) by Administering E-Selectin

The invention is a method and composition for inhibiting or treating symptoms of inflammatory demyelination or inflammation associated with autoimmune disorders. This is accomplished by administering recombinant E-selectin protein intranasally and resulting in E selectin-specific regulatory T-cells. These regulatory T-cells suppress activation of blood...

Published: 4/8/2024 | Inventor(s): Jacqueline Shukaliak-Quandt

Keywords(s): ANIMAL, Autoimmune, BBXXXX, BCXXXX, brain, Damage, EAE, Encephalomylelitis, e-selectin, EXPERIMENTAL, IMMUNOLOGICAL, Model, Multiple sclerosis, NB1HXX, NB1JXX, NB1XXX, NBXXXX, NXXXXX, PREVENTS, Tolerization

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Neurology

1 2 3

|

|

|

© 2024. All Rights Reserved. Powered by Inteum